Press Room

DDL 2019

Start
Wednesday, December 11, 2019 - 09:00
End
Friday, December 13, 2019 - 18:00
Location: Edinburgh, Scotland
Booth Number: 239





 

If you would like to find more about Hovione's full range of inhalation development servicesparticle engineering and development by design schedule a meeting with usour colleague Marcel Hogerheide will be pleased to meet with you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development









 

Schedule a meeting button | Hovione





























 

Hovione will present a set of 3 posters:

1. Commercial scale dosator-based capsule filling: the effect of process parameters on the aerodynamic performance of a carrier-based DPI

Poster Board 21

Author: Maria Braga



2. Nasal powder delivery: a step towards a biorelevant dissolution system

Poster Board 34

Author: Patrícia Henriques

3. Aerodynamic performance and imaging characterization of DPI formulations

Poster Board 43

Author: Rúben Chaves

4. Biorelevant dissolution to differentiate formulation performance for inhalation

Poster Board 58

Author: Beatriz Fernandes

 

 

Find here more details about the conference

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026